IEFA, SPOT, SE, TEVA: Large Inflows Detected at ETF
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2025
0mins
Should l Buy TEVA?
Source: NASDAQ.COM
52 Week Range and Current Price: The IEFA ETF has a 52-week low of $66.95 and a high of $78.9464, with the last trade recorded at $74.21.
ETF Trading Dynamics: ETFs operate like stocks but involve trading "units" that can be created or destroyed based on investor demand, affecting the underlying holdings and market flows.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEVA
Wall Street analysts forecast TEVA stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 35.350
Low
29.00
Averages
35.71
High
40.00
Current: 35.350
Low
29.00
Averages
35.71
High
40.00
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Teva Pharmaceuticals to Present at BofA Healthcare Conference
- Conference Schedule: Eric Hughes, Teva's EVP of Global R&D and Chief Medical Officer, will present at the BofA Securities Healthcare Conference on May 12, 2026, at 9:20 AM Pacific Time (12:20 PM Eastern Time), highlighting the company's latest advancements in biopharmaceuticals.
- Live Webcast Access: The presentation will be accessible via Teva's Investor Relations website, with archived versions available within 24 hours post-presentation and accessible for up to 30 days, ensuring timely access to critical information for investors.
- Company Transformation Strategy: Teva is transforming into a leading innovative biopharmaceutical company, committed to addressing patient needs through its world-class generics business, showcasing its innovation in neuroscience and immunology to further solidify its market position.
- Caution on Forward-Looking Statements: Teva cautions investors that the conference content may include forward-looking statements regarding financial guidance and future performance expectations, which are subject to various risks and uncertainties that could cause actual results to differ significantly from those anticipated.
See More
TEVA PHARMACEUTICALS: UBS Increases Price Target from $36 to $42
- Price Increase Announcement: Teva Pharmaceuticals has raised its target price from $36 to $42.
- Market Impact: This adjustment reflects a positive outlook for the company's performance in the pharmaceutical market.
See More
Latest Developments in the Biotech Sector
- Regulatory Approvals: Crinetics received European Commission approval for PALSONIFY to treat acromegaly in adults, becoming the first once-daily oral therapy in Europe, covering 27 EU member states, which is expected to significantly enhance market share.
- Acquisition Expansion: Teva is acquiring Emalex Biosciences for $700 million, bolstering its neuroscience pipeline and potentially accelerating the NDA submission for Ecopipam, thereby strengthening Teva's competitive position in the CNS disorders market.
- Clinical Trial Progress: Biomea Fusion's Icovamenib showed a 52% increase in mean C-peptide AUC in its Phase 2 trial for Type 1 Diabetes, indicating potential efficacy in early-stage patients, which may drive further development efforts.
- Market Reactions: Despite multiple approvals, AstraZeneca and Novartis saw their stock prices decline by 0.79% and 1.76% respectively, reflecting a cautious investor sentiment towards the biotech sector.
See More
Teva Exceeds All Sustainability Bond Targets
- Sustainability Achievements: Teva's 2025 Healthy Future Report reveals that it has surpassed all sustainability bond targets linked to approximately $7.5 billion in debt issuance, demonstrating significant progress in climate action and health equity.
- Greenhouse Gas Reduction: Teva has achieved a 39% reduction in Scope 1 and 2 greenhouse gas emissions since 2019, and a 32% reduction in Scope 3 emissions since 2020, both exceeding the 25% reduction targets, indicating proactive efforts in minimizing environmental impact.
- Expanded Patient Access: Through its global access to medicines programs, Teva has reached nearly 8 million people via product donations and approximately 399,000 through health system strengthening initiatives, showcasing the company's commitment to improving health outcomes worldwide.
- Compliance Training Coverage: More than 99% of Teva's active employees have completed compliance and ethics training, and 66% of significant suppliers have undergone sustainability performance evaluations, reflecting the company's strong standards for responsible and ethical practices across its operations.
See More
Teva Acquires Emalex to Boost Growth Strategy
- Acquisition Overview: Teva Pharmaceuticals will acquire neuroscience specialist Emalex for $700 million upfront and up to $200 million in potential milestones, effectively supporting Teva's 'pivot to growth' strategy aimed at enhancing its market position in neuroscience.
- New Drug Development Progress: Emalex's ecopipam, a first-in-class therapy for pediatric Tourette's syndrome, has secured a Phase III win and is expected to file for FDA approval in the second half of 2026, potentially becoming the first new drug in over a decade to enter the market and fill a significant gap.
- Market Competitive Advantage: Unlike existing dopamine D2 receptor-targeting medications, ecopipam targets the D1 receptor, which may offer improved efficacy and safety, addressing unmet needs in pediatric patients, and is projected to boost Teva's margin profile with peak U.S. sales reaching $1 billion by 2035.
- Strategic Investment Focus: While acquiring Emalex, Teva emphasizes its ongoing strategy to focus on late-stage, de-risked, and differentiated assets, particularly in neurology and inflammation, to support the continued growth of its innovative medicines portfolio without the pressure of an impending patent cliff.
See More
Blackstone's $400 Million Investment in Teva: A Strategic Bet
- Investment Scale and Strategic Significance: Blackstone Life Sciences' $400 million investment in Teva Pharmaceuticals in March 2023 reflects strong confidence in the new drug duvakitug, representing not just financial backing but a significant bet on Teva's future development.
- Drug Potential and Clinical Progress: Duvakitug, a monoclonal antibody targeting TL1A, is currently undergoing Phase 3 clinical trials for ulcerative colitis and Crohn's disease, with promising Phase 2 results showing durable efficacy over 44 weeks, indicating a broad market potential.
- Teva's Transformation and Market Recognition: Teva has evolved from a mere generic drug manufacturer to a leader in biopharmaceutical innovation, with credit rating agencies upgrading its rating to BB+, reflecting market confidence in its transformation.
- Opportunities and Risks for Investors: Blackstone's investment not only provides Teva with financial support but may also yield milestone payments and low single-digit royalties on global sales, suggesting that while risk-averse investors might hesitate, aggressive investors could find significant value in Teva, especially if duvakitug succeeds as anticipated.
See More
Teva Pharmaceuticals to Present at BofA Healthcare Conference
- Conference Schedule: Eric Hughes, Teva's EVP of Global R&D and Chief Medical Officer, will present at the BofA Securities Healthcare Conference on May 12, 2026, at 9:20 AM Pacific Time (12:20 PM Eastern Time), highlighting the company's latest advancements in biopharmaceuticals.
- Live Webcast Access: The presentation will be accessible via Teva's Investor Relations website, with archived versions available within 24 hours post-presentation and accessible for up to 30 days, ensuring timely access to critical information for investors.
- Company Transformation Strategy: Teva is transforming into a leading innovative biopharmaceutical company, committed to addressing patient needs through its world-class generics business, showcasing its innovation in neuroscience and immunology to further solidify its market position.
- Caution on Forward-Looking Statements: Teva cautions investors that the conference content may include forward-looking statements regarding financial guidance and future performance expectations, which are subject to various risks and uncertainties that could cause actual results to differ significantly from those anticipated.
See More
TEVA PHARMACEUTICALS: UBS Increases Price Target from $36 to $42
- Price Increase Announcement: Teva Pharmaceuticals has raised its target price from $36 to $42.
- Market Impact: This adjustment reflects a positive outlook for the company's performance in the pharmaceutical market.
See More
Latest Developments in the Biotech Sector
- Regulatory Approvals: Crinetics received European Commission approval for PALSONIFY to treat acromegaly in adults, becoming the first once-daily oral therapy in Europe, covering 27 EU member states, which is expected to significantly enhance market share.
- Acquisition Expansion: Teva is acquiring Emalex Biosciences for $700 million, bolstering its neuroscience pipeline and potentially accelerating the NDA submission for Ecopipam, thereby strengthening Teva's competitive position in the CNS disorders market.
- Clinical Trial Progress: Biomea Fusion's Icovamenib showed a 52% increase in mean C-peptide AUC in its Phase 2 trial for Type 1 Diabetes, indicating potential efficacy in early-stage patients, which may drive further development efforts.
- Market Reactions: Despite multiple approvals, AstraZeneca and Novartis saw their stock prices decline by 0.79% and 1.76% respectively, reflecting a cautious investor sentiment towards the biotech sector.
See More
Teva Exceeds All Sustainability Bond Targets
- Sustainability Achievements: Teva's 2025 Healthy Future Report reveals that it has surpassed all sustainability bond targets linked to approximately $7.5 billion in debt issuance, demonstrating significant progress in climate action and health equity.
- Greenhouse Gas Reduction: Teva has achieved a 39% reduction in Scope 1 and 2 greenhouse gas emissions since 2019, and a 32% reduction in Scope 3 emissions since 2020, both exceeding the 25% reduction targets, indicating proactive efforts in minimizing environmental impact.
- Expanded Patient Access: Through its global access to medicines programs, Teva has reached nearly 8 million people via product donations and approximately 399,000 through health system strengthening initiatives, showcasing the company's commitment to improving health outcomes worldwide.
- Compliance Training Coverage: More than 99% of Teva's active employees have completed compliance and ethics training, and 66% of significant suppliers have undergone sustainability performance evaluations, reflecting the company's strong standards for responsible and ethical practices across its operations.
See More
Teva Acquires Emalex to Boost Growth Strategy
- Acquisition Overview: Teva Pharmaceuticals will acquire neuroscience specialist Emalex for $700 million upfront and up to $200 million in potential milestones, effectively supporting Teva's 'pivot to growth' strategy aimed at enhancing its market position in neuroscience.
- New Drug Development Progress: Emalex's ecopipam, a first-in-class therapy for pediatric Tourette's syndrome, has secured a Phase III win and is expected to file for FDA approval in the second half of 2026, potentially becoming the first new drug in over a decade to enter the market and fill a significant gap.
- Market Competitive Advantage: Unlike existing dopamine D2 receptor-targeting medications, ecopipam targets the D1 receptor, which may offer improved efficacy and safety, addressing unmet needs in pediatric patients, and is projected to boost Teva's margin profile with peak U.S. sales reaching $1 billion by 2035.
- Strategic Investment Focus: While acquiring Emalex, Teva emphasizes its ongoing strategy to focus on late-stage, de-risked, and differentiated assets, particularly in neurology and inflammation, to support the continued growth of its innovative medicines portfolio without the pressure of an impending patent cliff.
See More
Blackstone's $400 Million Investment in Teva: A Strategic Bet
- Investment Scale and Strategic Significance: Blackstone Life Sciences' $400 million investment in Teva Pharmaceuticals in March 2023 reflects strong confidence in the new drug duvakitug, representing not just financial backing but a significant bet on Teva's future development.
- Drug Potential and Clinical Progress: Duvakitug, a monoclonal antibody targeting TL1A, is currently undergoing Phase 3 clinical trials for ulcerative colitis and Crohn's disease, with promising Phase 2 results showing durable efficacy over 44 weeks, indicating a broad market potential.
- Teva's Transformation and Market Recognition: Teva has evolved from a mere generic drug manufacturer to a leader in biopharmaceutical innovation, with credit rating agencies upgrading its rating to BB+, reflecting market confidence in its transformation.
- Opportunities and Risks for Investors: Blackstone's investment not only provides Teva with financial support but may also yield milestone payments and low single-digit royalties on global sales, suggesting that while risk-averse investors might hesitate, aggressive investors could find significant value in Teva, especially if duvakitug succeeds as anticipated.
See More
